Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer

开发用于治疗 KRAS 突变结直肠癌的 MTX-211

基本信息

  • 批准号:
    9891971
  • 负责人:
  • 金额:
    $ 97.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-02-01 至 2022-02-28
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Mekanistic Therapeutics seeks to design, discover, and develop anti-cancer agents that selectively inhibit multiple oncogenic pathways. Its lead agent MTX-211 was discovered in collaboration with the Leopold laboratory at University of Michigan. The overall objective of this project is to expediently advance MTX- 211 into development for the treatment of KRAS mutant colorectal cancer (CRC). Every year >130,000 new patients are diagnosed with colorectal cancer. At the time of diagnosis, approximately 20% of these patients present with metastatic disease. Currently, there are no approved treatments for metastatic CRC patients with activating mutations in KRAS. MTX-211 is a first-in-class highly selective dual inhibitor of PI3K and EGFR kinases, designed to attack KRAS oncogenic signaling using two orthogonal mechanisms. As such, it embodies a combination approach in a single molecule. Phase I aims focused on optimizing the synthetic process to scale-up production of MTX-211 and conducting a pilot mouse trial of primary xenograft models established from six different patients diagnosed with KRAS mutant CRC. All milestones were achieved providing preclinical proof-of-concept for pursuit of a clinical development path for MTX-211 that specifically targets the KRAS mutant CRC population. In Phase II, we propose to test a broader panel of KRAS mutant CRC models in an expanded efficacy trial that incorporates molecular profiling to identify prognostic markers that correlate with therapeutic outcome. At the same time, we propose to carry out early safety studies to further de-risk MTX-211 and strengthen the case for moving forward to future IND-enabling toxicology studies.
项目摘要 机械疗法旨在设计,发现和开发选择性抑制肿瘤的抗癌药物。 多种致癌途径。它的主要药物MTX-211是与利奥波德合作发现的。 密歇根大学的实验室。该项目的总体目标是方便地推进MTX- 211开发用于治疗KRAS突变型结直肠癌(CRC)。每年> 13万 新的患者被诊断患有结肠直肠癌。在诊断时,大约20%的人 存在转移性疾病的患者。目前,没有批准的转移性肿瘤的治疗方法。 具有KRAS激活突变的CRC患者。MTX-211是一流的高选择性双重抑制剂 PI 3 K和EGFR激酶,旨在使用两个正交的 机制等因此,它在单个分子中体现了组合方法。第一阶段的目标集中在 优化MTX-211的合成工艺,扩大生产规模, 从诊断为KRAS突变的六名不同患者建立的原发性异种移植模型的试验 《儿童权利公约》。实现了所有里程碑,为临床研究提供了临床前概念验证。 MTX-211特异性靶向KRAS突变型CRC人群的开发路径。在第二阶段, 我们建议在一项扩大的疗效试验中测试更广泛的KRAS突变型CRC模型, 结合分子谱分析以鉴定与治疗结果相关的预后标志物。 同时,我们建议开展早期安全性研究,以进一步降低MTX-211的风险,并加强 推进未来IND毒理学研究的案例。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Judith S Leopold其他文献

Judith S Leopold的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Judith S Leopold', 18)}}的其他基金

Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers
开发新的组合策略来克服结直肠癌对 KRASG12C 抑制的耐药性
  • 批准号:
    10512415
  • 财政年份:
    2022
  • 资助金额:
    $ 97.3万
  • 项目类别:
Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers
开发新的组合策略来克服结直肠癌对 KRASG12C 抑制的耐药性
  • 批准号:
    10666698
  • 财政年份:
    2022
  • 资助金额:
    $ 97.3万
  • 项目类别:
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers
开发治疗鳞状头颈癌的新型治疗分子
  • 批准号:
    10666868
  • 财政年份:
    2022
  • 资助金额:
    $ 97.3万
  • 项目类别:
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers
开发治疗鳞状头颈癌的新型治疗分子
  • 批准号:
    10325253
  • 财政年份:
    2021
  • 资助金额:
    $ 97.3万
  • 项目类别:
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
使用一流的双靶向 PI3K/EGFR 抑制剂对抗胰腺癌耐药性
  • 批准号:
    10197037
  • 财政年份:
    2019
  • 资助金额:
    $ 97.3万
  • 项目类别:
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
使用一流的双靶向 PI3K/EGFR 抑制剂对抗胰腺癌耐药性
  • 批准号:
    10652462
  • 财政年份:
    2019
  • 资助金额:
    $ 97.3万
  • 项目类别:
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
使用一流的双靶向 PI3K/EGFR 抑制剂对抗胰腺癌耐药性
  • 批准号:
    10432048
  • 财政年份:
    2019
  • 资助金额:
    $ 97.3万
  • 项目类别:
Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer
开发 EGFR 和 PI3 激酶双重选择性小分子抑制剂来治疗 BRAF 突变结直肠癌
  • 批准号:
    10377535
  • 财政年份:
    2018
  • 资助金额:
    $ 97.3万
  • 项目类别:
Development of a Dual and Selective Small Molecule Inhibitor of EGFR and PI3 Kinase to Treat BRAF Mutant Colorectal Cancer
开发 EGFR 和 PI3 激酶双重选择性小分子抑制剂来治疗 BRAF 突变结直肠癌
  • 批准号:
    9896781
  • 财政年份:
    2018
  • 资助金额:
    $ 97.3万
  • 项目类别:
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer
开发用于治疗 KRAS 突变结直肠癌的 MTX-211
  • 批准号:
    9255740
  • 财政年份:
    2017
  • 资助金额:
    $ 97.3万
  • 项目类别:

相似海外基金

Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
  • 批准号:
    2335802
  • 财政年份:
    2024
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Standard Grant
Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
  • 批准号:
    2335801
  • 财政年份:
    2024
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Standard Grant
A Longitudinal Study of the Relationship between Participation in a Comprehensive Exercise Program and Academic Achievement
参加综合锻炼计划与学业成绩之间关系的纵向研究
  • 批准号:
    24K14615
  • 财政年份:
    2024
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Collaborative Research: Characterizing Best Practices of Instructors who Have Narrowed Performance Gaps in Undergraduate Student Achievement in Introductory STEM Courses
合作研究:缩小本科生 STEM 入门课程成绩差距的讲师的最佳实践
  • 批准号:
    2420369
  • 财政年份:
    2024
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Standard Grant
Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
  • 批准号:
    2335800
  • 财政年份:
    2024
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Standard Grant
WTG: Diffusion of Research on Supporting Mathematics Achievement for Youth with Disabilities through Twitter Translational Visual Abstracts
WTG:通过 Twitter 翻译视觉摘要传播支持残疾青少年数学成就的研究
  • 批准号:
    2244734
  • 财政年份:
    2023
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Standard Grant
The Impact of Emotional Experiences of Pride on Long-Term Goal Achievement Behaviors in Elite Athletes
骄傲的情感体验对优秀运动员长期目标实现行为的影响
  • 批准号:
    23K16740
  • 财政年份:
    2023
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Meta-Analysis of the Instructional-Relational Model of Student Engagement and Math Achievement: A Moderation and Mediation Approach
学生参与度和数学成绩的教学关系模型的元分析:一种调节和中介方法
  • 批准号:
    2300738
  • 财政年份:
    2023
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Standard Grant
Improving maths achievement in children with speech, language, and communication needs through 'collaborative vocabulary teaching'
通过“协作词汇教学”提高有言语、语言和交流需求的儿童的数学成绩
  • 批准号:
    2890475
  • 财政年份:
    2023
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Studentship
HSI Institutional Transformation Project: Retention and Achievement for Introductory STEM English Learners (RAISE)
HSI 机构转型项目:STEM 英语入门学习者的保留和成就 (RAISE)
  • 批准号:
    2225178
  • 财政年份:
    2023
  • 资助金额:
    $ 97.3万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了